Subscribe
Preliminary findings of the GIMEMA LAL 1509 total therapy protocol, which evaluated the tyrosine kinase inhibitor dasatinib plus steroids as induction therapy in adult patients with de novo Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) were presented previously.1 At ASH [ Read More ]
Pediatric patients with acute lymphoblastic leukemia (ALL) achieve considerably higher disease-free survival (DFS) rates with current chemotherapy regimens than adults with ALL. Young adults have been shown to achieve superior survival outcomes when treated with native E coli asparaginase-based regimen.1 The [ Read More ]
Elderly patients with acute lymphoblastic leukemia (ALL) show poor tolerance of intensive chemotherapy, which is the rationale for evaluation of targeted nonmyelosuppressive agents in combination with effective low-intensity chemotherapy in this population. Inotuzumab ozogamicin (IO) is an anti-CD22 monoclonal antibody [ Read More ]